Skip to content

A randomized controlled trial for assessing the effectiveness and safety of patients with malignant abdominal or pelvic tumors receiving prolonged postoperative thromboprophylaxis

A randomized controlled trial for assessing the effectiveness and safety of patients with malignant abdominal or pelvic tumors receiving prolonged postoperative thromboprophylaxis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036497
Enrollment
Unknown
Registered
2020-08-23
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

venous thromboembolism

Interventions

Sponsors

Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients are clearly pathologically diagnosed abdominal or pelvic malignant tumors (from general surgery department, gynecology department, urology department, etc.; including laparoscopic and open surgery); 2. Caprini score >=5 points; 3. Expecting life span >=6 months; 4. Patients need to receive routine VTE prophylaxis during hospitalization after operation (physical prevention and pharmaceutical prevention); 5. Tumor stage >=2.

Exclusion criteria

Exclusion criteria: 1. Catheter-related DVT; 2. Past history of VTE or vascular diseases, such as varicose veins and phlebitis; 3. Having received other surgical treatment in 6 months; 4. Clinical manifestations of complicating DVT/PE, but not comfirmed by imaging examination; 5. Past history of blood disorders or severe coagulation dysfunction; 6. Severe liver and renal dysfunction; 7. Long-term use of antithrombotic drugs before surgery; 8. Incomplete clinical data (diagnosis is not clear, medical history is incomplete, medication records are incomplete, etc.); 9. Presence of contraindications to heparin/anticoagulation, heparin allergy/HIT; 10. With heart failure, respiratory failure, refractory hypertension; 11. Pregnancy/lactation.

Design outcomes

Primary

MeasureTime frame
VTE occurrence in the 4th week after operation;VTE occurrence in the 8th week after operation;all-cause mortality in the 4th week after operation;VTE occurrence in the 8th week after operation;all-cause mortality in the 4th week after operation;all-cause mortality in the 8th week after operation;duration from operation to VTE occurrence;bleeding events;

Countries

China

Contacts

Public ContactYong Lu

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

18917762053@163.com+86 18917762053

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026